Artelo Biosciences Announces $9.475 Million Private Placement to Launch Solana Financial Strategy

Nasdaq-listed Artelo Biosciences (NASDAQ: ARTL) announced the launch of an underwritten public offering of common stock and/or prepaid warrants, with RF Lafferty & Co., Inc. acting as sole bookrunner. Additionally, Artelo announced a $9.475 million private fundraising round to launch its Solana blockchain-based financial strategy, becoming one of the first companies to adopt the Solana cryptocurrency as its core reserve asset.